Home
About
Company Profile
History
Corporate Philosophy
Honors
Holding company
Social Responsibility
Factory Tour
Management Team
Investor Relations
Innovative R&D
R&D Team
R&D Conditions
Technology Platform
Research Collaboration
Research paper
R&D platform
Products under development
Sales & Marketing
Listed Products
Vaccination Site Notice
Batch Release Status
Pharmaceutical Representative Filing Information
Delivery Provider Disclosure
Mandatory Vaccine Insurance
Blog
Hundred Grams News
Employee Activities
Industry Information
Visualized Periodic Reports
Supervisory Management
GMP Implementation Status
Quality Management
Recall Status
Undergo inspection
Penalty Details
邮箱：bcht@bchtpharm.com
电话：400-8845-777
BLOG
20
2025/10
“Foster a Rational Investment Mindset and Enhance Risk Awareness” — “2025 World Investor Week” Campaign
16
2025/09
“Safeguarding Financial Rights and Promoting a Better Life” — 2025 Financial Education Awareness Week
09
Phase I Clinical Trial of Baik Bio’s HSV-2 mRNA Vaccine Launched in Beijing!
03
2025/07
Pooling Strength in Kuala Lumpur: Ushering in a New Chapter of Southeast Asian Cooperation — Bio-Thera Solutions Makes Its Debut in Southeast Asia
10
2025/06
Baike Biotech’s independently developed “Adsorbed Acellular DTP (Three-Component) Combined Vaccine” Has Initiated Phase III Clinical Trials. Baike Biotech’s independently developed “Adsorbed Acellular DTP (Three-Component) Combined Vaccine” Has Initiated Phase III Clinical Trials.
05
Announcement by Changchun Beacon Biotechnology Co., Ltd. on the Voluntary Disclosure of the Approval of the Clinical Trial Application for the Recombinant Shingles Vaccine (CHO Cells)
